Gdansk

Futó vizsgálatok

• Még nem toboroz

  An Open-Label Study to Evaluate the Long-Term Safety and Efficacy of ALXN2220 in Adults With Transthyretin Amyloid Cardiomyopathy

  NCT07789483· 3. fázis· Forrás

• Toboroz

  A Phase III, Multicentre Study to Evaluate Consolidation Treatment With AZD0120 Compared With ASCT, in Participants With Newly Diagnosed Multiple Myeloma Who Are Transplant Eligible (DURGA-6).

  NCT07735637· 3. fázis· Forrás

• Toboroz

  Roll-over Study for Participants Who Have Completed a Previous Clinical Study With Benralizumab (Fasenra) and Benefit From Continued Treatment

  NCT07444567· 3. fázis· Forrás

• Toboroz

  An Open-label Study to Investigate the Efficacy and Safety of Dato-DXd + Rilvegostomig vs SoC in Adult Participants With High-risk MIUC

  NCT07720284· 3. fázis· Forrás

• Toboroz

  Study of AZD0120 in Newly Diagnosed Multiple Myeloma Ineligible for ASCT

  NCT07764978· 3. fázis· Forrás

• Toboroz

  A Phase IIIb Study to Evaluate Camizestrant Plus Ribociclib in ER-positive, HER2-negative Advanced Breast Cancer

  NCT07647328· 3. fázis· Forrás

• Toboroz

  AZD2265 Compared With Standard of Care in PSMA-positive Metastatic Castration-resistant Prostate Cancer (VECTRA-01)

  NCT07611110· 3. fázis· Forrás

• Toboroz

  A Study Comparing AZD0120, a Dual-targeted CAR-T Against B-cell Maturation Antigen (BCMA) and CD19, Versus Standard Regimens in Participants With Relapsed Refractory Multiple Myeloma (DURGA-4)

  NCT07391657· 3. fázis· Forrás

• Toboroz

  Ravulizumab Treatment Outcomes in Patients With Generalized Myasthenia Gravis

  NCT06909253· Forrás

• Fut, nem toboroz

  Anifrolumab Real-world Treatment Outcomes in Systemic Lupus Erythematosus

  NCT06673043· Forrás

• Fut, nem toboroz

  Real-life Treatment Outcomes of Ravulizumab in PNH

  NCT06633536· Forrás

• Toboroz

  Study to Evaluate the Effect of Balcinrenone/Dapagliflozin in Patients With Heart Failure and Impaired Kidney Function

  NCT06307652· 3. fázis· Forrás

• Fut, nem toboroz

  Study of ALXN2220 Versus Placebo in Adults With ATTR-CM

  NCT06183931· 3. fázis· Forrás

• Toboroz

  A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer (TROPION-Breast05)

  NCT06103864· 3. fázis· Forrás

• Fut, nem toboroz

  A Long-term Safety and Efficacy Study of Danicopan as an Add-on Therapy to Complement Component 5 Inhibitor (C5i) in Participants With PNH

  NCT05389449· 3. fázis· Forrás

• Toboroz

  A Phase I/IIa Study of AZD8205 Given Alone or Combined, in Participants With Advanced/Metastatic Solid Malignancies

  NCT05123482· 1/2. fázis· Forrás

• Fut, nem toboroz

  Phase I Study to Assess the Effect of Food on the PK and Gastrointestinal Tolerability of Selumetinib in Adolescent Children With Neurofibromatosis Type 1 Related Plexiform Neurofibromas

  NCT05101148· 1. fázis· Forrás

• Fut, nem toboroz

  Study of AZD5305 as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Malignancies

  NCT04644068· 1/2. fázis· Forrás

• Fut, nem toboroz

  A Phase 2 Study of T-DXd in Patients With Selected HER2 Expressing Tumors

  NCT04482309· 2. fázis· Forrás

• Fut, nem toboroz

  Durvalumab or Placebo in Combination With Gemcitabine/Cisplatin in Patients With 1st Line Advanced Biliary Tract Cancer (TOPAZ-1)

  NCT03875235· 3. fázis· Forrás

• Fut, nem toboroz

  A Study of Durvalumab as Consolidation Therapy in Non-Small Cell Lung Cancer Patients

  NCT03706690· 3. fázis· Forrás

• Fut, nem toboroz

  Study of Durvalumab Given With Chemotherapy, Durvalumab in Combination With Tremelimumab Given With Chemotherapy, or Chemotherapy in Patients With Unresectable Urothelial Cancer

  NCT03682068· 3. fázis· Forrás

• Fut, nem toboroz

  AZD9291 in Combination With Ascending Doses of Novel Therapeutics

  NCT02143466· 1. fázis· Forrás

• Fut, nem toboroz

  Assess Efficacy & Safety of Selumetinib in Combination With Docetaxel in Patients Receiving 2nd Line Treatment for v-Ki-ras2 Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Positive NSCLC

  NCT01933932· 3. fázis· Forrás

• Fut, nem toboroz

  Randomized, Double-blind Study Comparing Tremelimumab to Placebo in Subjects With Unresectable Malignant Mesothelioma

  NCT01843374· 2. fázis· Forrás

Egyszerre toboroz

Hány vizsgálat toboroz itt egyszerre ugyanarra az indikációra. Darabszám, nem értékelés.

• Mielóma multiplex3 toboroz
• Amiloidózis1 toboroz
• ANCA-asszociált vasculitis1 toboroz
• Asztma1 toboroz
• Áttétes emlőrák1 toboroz
• Hólyagrák1 toboroz
• Méhtestrák1 toboroz
• Myasthenia gravis1 toboroz
• Petefészekrák1 toboroz
• Prosztatarák1 toboroz
• Szívelégtelenség1 toboroz
• Tripla negatív emlőrák1 toboroz
• Tüdőrák1 toboroz

Kutatók

Ide még nem kötődik kutató.

Lezárt vizsgálatok

• Lezárult

  Study to Evaluate Efficacy and Safety of Tezepelumab in Reducing Oral Corticosteroid Use in Adult Patients With Severe Asthma

  NCT05274815· 3. fázis· Forrás

• Leállították

  Effect of Sodium Zirconium Cyclosilicate on Arrythmia-related Cardiovascular Outcomes in Participants on Chronic Hemodialysis With Recurrent Hyperkalemia (DIALIZE-Outcomes)

  NCT04847232· 3. fázis· Forrás

• Lezárult

  Danicopan as Add-on Therapy to a C5 Inhibitor in Paroxysmal Nocturnal Hemoglobinuria (PNH) Participants Who Have Clinically Evident Extravascular Hemolysis (EVH)(ALPHA)

  NCT04469465· 3. fázis· Forrás

• Lezárult

  Phase III Study to Determine Efficacy of Durvalumab in Stage II-III Non-small Cell Lung Cancer (NSCLC) After Curative Intent Therapy.

  NCT04642469· 3. fázis· Forrás

• Lezárult

  Study of Durvalumab Following Radiation Therapy in Patients With Stage 3 Unresectable NSCLC Ineligible for Chemotherapy

  NCT04249362· 2. fázis· Forrás

• Lezárult

  Assessment of the Efficacy and Safety of Olaparib Monotherapy Versus Physicians Choice Chemotherapy in the Treatment of Metastatic Breast Cancer Patients With Germline BRCA1/2 Mutations.

  NCT02000622· 3. fázis· Forrás

• Lezárult

  A Global Study to Assess the Effects of MEDI4736 (Durvalumab) in Patients With Locally Advanced or Metastatic Non Small Cell Lung Cancer

  NCT02087423· 2. fázis· Forrás